Loading...
Buprenorphine — a partial opioid agonist prescribed as tablets or oral film either singly or in combination to treat opioid addiction — has become the leading cause of opioid hospital admissions in children and adolescents.
Now, investigators have conducted an observational surveillance study to assess the extent to which unit-dose packaging (UDP) of buprenorphine products, initiated by several drug makers in 2010, has reduced unintentional pediatric exposures to buprenorphine-naloxone film. The researchers surveyed data on children younger than 6 years from the RADARS (Researched Abuse, Diversion, Addiction-Related Surveillance) poison center program, which covers 290 million individuals from 48 states, and divided the study into three peri…